NYSE: TMHCTaylor Morrison Home Corp Stock
$56.44+1.53 (+2.79%)
Updated Apr 17, 2025
TMHC Price
$56.44
Fair Value Price
N/A
Market Cap
$5.74B
52 Week Low
$51.90
52 Week High
$75.49
P/E
6.7x
P/B
0.98x
P/S
0.78x
PEG
1.19x
Dividend Yield
N/A
Revenue
$8.17B
Earnings
$883.31M
Gross Margin
24.3%
Operating Margin
14.28%
Profit Margin
10.8%
Debt to Equity
0.58
Operating Cash Flow
$210M
Beta
1.41
Next Earnings
Apr 28, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TMHC Overview
Taylor Morrison Home Corporation builds single and multi-family detached and attached homes and develops lifestyle and master-planned communities in the U.S.. It also develops and constructs multi-use properties consisting of commercial space, retail, and multi-family properties under the Urban Form brand name. Other offerings include title insurance, closing settlement services, and financial services. Taylor Morrison was founded in 1936 and is headquartered in Scottsdale, AZ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TMHC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Construction
Industry Rating
B
TMHC
Ranked#5 of 23
Ranked#5 of 23
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $38.85 | B | |
| $106.19 | B | |
| $24.21 | B |
Be the first to know about important TMHC news, forecast changes, insider trades & much more!
TMHC News
Overview
Due Diligence Score
–
Industry Average (34)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TMHC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TMHC ($56.44) is trading below its intrinsic value of $62.16, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TMHC is good value based on its earnings relative to its share price (6.7x), compared to the US market average (27.98x)
P/E vs Market Valuation
TMHC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more TMHC due diligence checks available for Premium users.
Valuation
TMHC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
6.7x
Industry
9.44x
Market
27.98x
TMHC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TMHC is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
TMHC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.98x
Industry
1.5x
TMHC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TMHC price to earnings growth (PEG)
For valuing profitable companies with growth potential
TMHC is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
TMHC's financial health
Profit margin
Revenue
$2.4B
Net Income
$242.5M
Profit Margin
10.3%
TMHC's Earnings (EBIT) of $1.17B... subscribe to Premium to read more.
Interest Coverage Financials
TMHC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.3B
Liabilities
$3.4B
Debt to equity
0.58
TMHC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TMHC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$438.2M
Investing
-$54.1M
Financing
-$154.3M
TMHC's operating cash flow ($210.08M)... subscribe to Premium to read more.
Debt Coverage Financials
TMHC vs Construction Stocks
Taylor Morrison Home Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.